Clinical Trial · NCT05990998

A Head-to-head Comparison of [68Ga]Ga-FAPI and [68Ga]Ga-TATE PET/CT in Patients With Nasopharyngeal Carcinoma: a Single-center, Prospective Study

Overview

Both fibroblast activation protein (FAP)-targeted imaging and somatostatin receptors (SSTR)-targeted imaging were the promising imaging modalities for the diagnosis of primary and metastatic nasopharyngeal carcinoma (NPC). This prospective study is going to investigate to compare the diagnostic efficacy of 68Ga-FAPI and 68Ga-DOTATATE in detecting primary and metastatic NPC lesions, thereby obtaining a more accurate examination method of NPC.

Sponsor

First Affiliated Hospital of Fujian Medical University

Phase

Phase 1/2

Contacts

Weibing Miao, MD

miaoweibing@126.com

86-0591-87981618

jieling zheng

775304265@qq.com

86-599-87981619

ClinicalTrials.gov

NCT05990998

Drug / Compound

Isotope(s):
Target(s):